FCGR3A and follicular lymphoma: Recently, a phase I trial investigating a Fc-engineered antibody targeting CD20 in follicular lymphoma patients has suggested encouraging results even in patients with the less favorable FcγRIIIa-F allotype (Forero-Torres et al., 2012).